Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Big things happening here with Radient. I love that they are extracting nicotine now. We are here very early and I love that.
Radient Technologies Inc. Announces Industrial-Scale Capability for the Extraction of Nicotine from Tobacco
They are still working on the deal structure with Aurora so it may be a while before things pick up. My guess is early next year before it takes off.
End of year financials out.
https://mobile.tmxmoney.com/quote/readnews/?id=8277115073776641&symbol=RTI
Yes it will but now I am not so sure a buyout is coming. I think it will just be exclusive rights for cannabis extraction to use the MAP tech for any and all of Auroras sites including Australia and Germany.
GLTA
It will certainly be interesting to see what the deal is that they come up with.
Anyone else think a buyout from Aurora is coming sooner rather than later? Volume was big today and has been up while PPS is going down. Smells like a buyout to me.
Updated collaboration info with Aurora:
https://mobile.tmxmoney.com/quote/readnews/?id=8366613769681844&symbol=RTI
Glad I got my positive day today. Was a little nervous at first. Still looking forward to more people finding this gem.
Yea they had to issue just over 200k shares to Aurora @.48 CAD its in the deal they made. They also pay Aurora 50k per quarter I believe.
But yes I can see Aurora buying them out or taking a much larger ownership in the not too distant future.
Interesting how this moves with Aurora. Perhaps we may see some new highs here soon.
http://www.firmenpresse.de/pressrelease546227/aurora-and-radient-technologies-announce-positive-results-from-research-joint-venture.html
Aurora and Radient Technologies Announce Positive Results from Research Joint Venture
Collaboration Validates that Radient's Proprietary Extraction Technology Offers Superior Cannabinoid Extraction Efficiency and Significantly Higher Throughput than Conventional Processes
/EINPresswire.com/ -- VANCOUVER, BRITISH COLUMBIA and EDMONTON, ALBERTA--(Marketwired - Jun 5, 2017) - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX VENTURE:ACB)(OTCQX:ACBFF)(FRANKFURT:21P)(WKN:A1C4WM) and Radient Technologies ("Radient") (TSX VENTURE:RTI) are pleased to announce the successful completion of their Joint Venture Research Activity ("JV"), confirming the effectiveness of Radient's proprietary MAP™ Technology and associated continuous flow design for extracting cannabinoids from dried cannabis.
On December 14, 2016, Radient and Aurora executed a Memorandum of Understanding ("MOU") to evaluate an exclusive partnership for the Canadian market with regard to the joint development and commercialization of superior and standardized cannabinoid extracts. The first element of the collaboration was the execution of a joint research project to assess the feasibility of applying Radient's proprietary technology for the extraction of cannabinoids from cannabis, including the establishment of parameters of extraction yields, recovery rates of available cannabinoids, purity of the extracts obtained, and the determination of cannabinoids and terpene profiles. The feasibility study also included an assessment of the potential processing throughput achievable using Radient's large-scale continuous-flow MAP™ extractor, based upon established extraction conditions.
Radient's MAP™ technology enables precise control of temperature and extraction time of continuously flowing material, both of which affect purity and extract profile. This careful control of extraction parameters and product quality is something that is impossible to achieve at large scale using conventional methods. Extremely high (quantitative) recovery of available cannabinoids is possible in extraction times that are shaved from hours to minutes.
The study was conducted in two phases: bench-scale screening experiments of MAP™ extraction conditions; and scaled-up experiments under preferred extraction conditions. The analytical data from the research project were verified and confirmed by Anandia Labs Inc., a leading Canadian independent cannabis testing laboratory.
Key findings:
Consistently high extraction efficiencies of up to 98% (quantitative recovery) were observed compared to 80 - 85% typical for conventional technologies;
Exceptionally short processing times of as little as five minutes were achieved, as compared to approximately 6 hours for currently used commercial technologies;
Consistently high purity levels were observed for the extracts produced, at least on par with those achieved using conventional methods;
The research data indicate that throughputs in excess of 1,500 kg per day can potentially be achieved using Radient's proprietary large-scale continuous-flow MAP™ extractor, many times higher than what can be achieved using conventional methods;
Replication of this technology in other jurisdictions on a larger or smaller scale is feasible;
Extract profiles obtained during the project show near full preservation of cannabinoid and terpene profiles in the extracts.
Based on the positive results of the study Radient and Aurora have agreed to negotiate an exclusive development and commercialization agreement for the use of Radient's technology, and to continue their exclusive Joint Venture for additional scientific Research and Development of cannabis and hemp products.
"These results clearly validate the game changing nature of Radient's technology for the cannabis sector," said Terry Booth, CEO of Aurora. "The ability to produce high-purity concentrates at very high throughputs, while preserving terpene profiles, will provide a substantial competitive advantage for us in addressing the high- growth concentrates market. We see a number of factors that will require a significant expansion of production capacity for extracts, including our own expanding national and international footprint, the continued strong growth of the medical market in Canada, Germany and Australia, and the commencement of Canadian adult usage sales anticipated for July of 2018. The exclusive use of Radient's technology positions us as the clear leader in this field, which we believe will enable Aurora to capture a significant share of this high-margin market."
Booth concluded, "Aurora is very pleased to be a significant shareholder of Radient, and as part of our partnership with them, plan on continuing to hold a significant position in Radient."
Radient's CEO, Denis Taschuk, stated, "The positive outcome of the joint research project is a key milestone in the commercial development of Radient. With these results in our pocket, we are now able to commercialize our technology in what has become the fastest growing sector of the North American economy. We are very pleased to embark on this journey with Aurora, who have proven to embrace innovation and who have developed one of the strongest brands within the cannabis industry, both in Canada and internationally."
Radient also announces that, pursuant the terms of the convertible debenture issued to Aurora on February 13, 2017, Radient will make the first quarterly interest payment of $50,000 to Aurora through the issuance of additional units to Aurora ("Units"). Each Unit consisting of one common share and one common share purchase warrant.
The interest payment was payable to Aurora on May 13, 2017 and the conversion price for the issuance of the Units is $0.48 being Radient's closing trading price on Friday May 12, 2017. Based on this conversion price, Radient will issue 104,167 common shares and 104,167 common share purchase warrants to Aurora in satisfaction of the interest payment. Each common share purchase warrant will entitle Aurora to acquire one additional common share of Radient at an exercise price of $0.48 per share. The issuance of the Units to Aurora is subject to final approval of the TSX Venture Exchange and the Units will be subject to a four month hold period.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island. Aurora also recently aquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ("EU"), based in Berlin, Germany. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the only Australian company licensed to conduct research on and cultivate medical cannabis, Aurora's common shares trade on the TSX-V under the symbol "ACB". Visit www.auroramj.com for more information.
About Radient
Radient extracts natural compounds from a range of biological materials using its proprietary MAP™ natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.
News and it's good!!!
https://mobile.tmxmoney.com/quote/readnews/?id=8366613769681844&symbol=RTI
What I love about Radient is that its share structure is set up to really move.
We should hopefully be getting news sometime this week. Last PR stated May 31st for completion pending 3rd party verification being done by Anandia labs for pesticides, potency etc.
From the PR from Aurora on May 15 2017:
Completed phase II of the research collaboration with Radient Technologies Inc. ("RTI"), and a report is expected from RTI, subject to confirmation of analytical results from Anandia Labs, by May 31, 2017.
Here's to a successful partnership or possible merger/acquisition between Aurora and Radient.
GLTA
ACBFF
RDDTF
Another great day for Radient. Seems to be riding the SMA's up to 60 cents.
Wasn't a big deal
Looks like it may have been the expansion they are working on not sure but production was not affected.
http://www.cbc.ca/beta/news/canada/ottawa/fire-hershey-factory-smiths-falls-1.4135916
Yes it was a nice day.
Holy crap I'll have to see what I can find on that I haven't owned tweed stock in over a year but will be interesting to see what happened.
Solid day today. My guess is another up day tomorrow. :)
Also there was a fire/explosion at the Tweed facility.
Good question but thats anyones guess. I think that they would fully merge the company with Aurora to make it a one step process. That being said I think Aurora would likely keep board members from Radient and so I think a similar deal that happened with Pedanios. I personally wouldnt think about buyout scenarios until Aurora is a year into producing out of Aurora Sky. Getting some revenues. Working out the kinks. One step at a time, you know?
Right looks like a good day.
So if Aurora decides to buy Radient what type of deal do you think they will strike? a full on cash buyout or maybe something similar to Pedanios deal?
Awesome! Pumped to wake up and see that Radient is getting some love after the Aurora news.
Yes I can definitely see them buying out Radient we already made a 19-20% investment so what's a few more million to add around 30-40% to our bottom line over the coming years. IMO oils are going to be the future, young people like to vape and old people like the bud or maybe a little of both but I see young people vaping more than smoking.
I would not be surprised if we get another whammy in the next few weeks with a buyout from Aurora. IMO I think it happens sooner rather than later as the price for RDDTF will only increase over the coming months. They do use the MAP tech for the food and beverage industry as well so we have to consider that.
Either way I just hope the tech works during production ramp up and is viable for us to use. I own 80k shares here and 100k in ACBFF.
GLTA
RDDTF
ACBFF
Yea me too. I got into this one when it was in the upper .50's so I have been down a while waiting for something to kick it in the ass and get it going. Hopefully the PR from Aurora will help but I think we hear something very soon about the collaboration update, the last PR from RTI stated May 31st.
Aurora could very well buy Radient down the road. Of course that is just my opinion but it makes sense on quite a few levels. Why wouldnt Aurora buy this company out and integrate it into part of its process to relieve itself of a middle man. Once Aurora gets going in a few years I could see this potentially happening. In the meantime what we can focus on are the deals Aurora is making which means more marijuana Radient will have to process for them.
Looking forward to Tuesdays open. I wonder if Auroras latest news will give this stock a little more pep.
So what are you saying Aurora will buy RDDTF?
Ready Aurora NR today and keeep in mind we are the exclusive extraction company...RDDTF will not be around by year end.
AURORA ACQUIRES GERMAN MEDICAL CANNABIS MARKET LEADER PEDANIOS GMBH
Aurora Cannabis Inc. has acquired Pedanios GmbH, a leading wholesale importer, exporter and distributor of medical cannabis in the European Union.
Pedanios, a federally licensed medical and narcotic wholesale and GMP-(good manufacturing practices)-inspected narcotic import company, holds all relevant licences and permits, and has been successfully importing, exporting and distributing cannabis for medical purposes since December, 2015, into and within the EU.
In January, 2017, German parliamentarians unanimously passed a new medical cannabis law, which appointed physicians as gatekeepers to access, established pharmacies as the point of sale and introduced full insurance cost coverage for medical cannabis patients across the country. In March, 2017, when the new law came into force, Pedanios's monthly sales immediately doubled, and growth continues to accelerate as Germany's 80 million citizens begin to benefit from the improvements to patient access guaranteed by the new law.
Pedanios wholesales medical cannabis to a growing number of pharmacies -- over 750 as of today -- and offers the widest selection of products of any distributor in the German market, including 10 of the 14 products approved by the Bundesopiumstelle, a body of the German federal health ministry. All of Pedanios's existing supply contracts will remain in place.
"This is a transformational acquisition for Aurora and a key step in our aggressive international expansion strategy," said Neil Belot, Aurora's chief global business development officer. "The transaction will ensure ongoing and increasing high-quality product is available to fuel Pedanios's rapid growth, while positioning Aurora and Pedanios to seize upon opportunities together in Germany and the EU's emerging cannabis industry."
"Pedanios, with first-mover success in the EU, has proven itself as one of the world's most trusted and scalable importers, exporters and distributors of wholesale medical cannabis. Patients, physicians and pharmacies across the EU recognize the Pedanios brand as the trusted source for high-quality GMP-certified medical cannabis," said Terry Booth, chief executive officer of Aurora. "The Pedanios team share Aurora's vision, our high standards and our intentions to play a leading role in shaping the future of the global cannabis industry. In addition, because the average market prices are higher in Germany than in Canada, we expect German sales to positively impact our average sales price per gram."
"Canada and Germany are among the world leaders in medical cannabis, and as trailblazers in our respective countries, Pedanios and Aurora are well positioned to continue to drive innovation, expand our distribution network and capture significant global market share," said Patrick Hoffmann, Pedanios's co-founder and executive partner. "We look forward to the synergies that our combined companies will deliver to shareholders and stakeholders alike."
Under the terms of the purchase agreement, dated May 18, 2017, Aurora will pay a consideration to holders of Class B securities of Pedanios approximately 3,421,756 common shares of Aurora, priced at $2.14 per share. In addition, a total consideration of approximately $13,565,000 in cash and common shares is payable to the holders of Class A common shares of Pedanios, which are held by the two founders/managing directors of Pedanios who will continue to run the company. The cash portion for the two founders is $3.02-million, and the share portion is 4,895,026 common shares of Aurora, priced at $2.14 per share, of which 17 per cent will become free trading four months after closing, with the balance becoming unrestricted in equal instalments on a quarterly basis over 27 months, commencing in February, 2018. Total shares of Aurora being issued over three years represent less than 2 per cent of total shares outstanding. Aurora's cash balance as of May 15, 2017, was $165-million. Values herein have been calculated based on an exchange rate of 1.51 Canadian dollars to one euro.
Pedanios, over the last 90 days, has achieved cash-flow-positive operations, with gross revenues of approximately $1.15-million and costs of approximately $1-million. Revenues for May, up to and including May 26, 2017, were approximately $500,000, reflecting a 410-per-cent increase in the daily sales pace as compared with average for the eight months prior to the introduction of the new law, and an increase over the April and March, 2017, averages of 70 per cent and 108 per cent, respectively.
About Aurora Cannabis Inc.
Aurora's wholly owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's access to cannabis for medical purposes regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, and is currently constructing a second 800,000-square-foot production facility, known as Aurora Sky, at the Edmonton International Airport. Also, it has acquired and is undertaking completion of a third 40,000-square-foot production facility in Pointe-Claire, Que., on Montreal's West Island.
travyyy:
Looking at the charts on the U.S side it appears that it was. Someone snatched up 159,000 shares so I'll take that as someone knows something good. And another day over 1 million traded on the Canadian side big numbers for this stock over the last few weeks.
I think we see an update pretty soon with ACBFF, and I think it will be good news. ACBFF was halted for news all day yesterday but no PR was put out yet so something big is coming IMO
GLTA
RDDTF
ACBFF
Cannabis Companies Leveraging Biotech Enhancements to Boost Improved Purity of Medicinal Marijuana Treatments and Products
PALM BEACH, Florida, May 16, 2017 /PRNewswire/ --
The influence of biotech advancements in the cannabis industries continues to be apparent as more and more companies focus upon various aspects of biotechnology to enhance operations and in turn boost revenues. With a growing population and finite natural resources, the challenge to produce higher quality therapies, treatment and increasing the purity of legal marijuana products while protecting the consumer is real while advances in biotechnology are quickly becoming a vital tool to help the legal medical marijuana industry get there. Companies focused on advancing high quality products for the industry include: Vinergy Resources Ltd. (OTC: VNNYF) (CSE: VIN), Terra Tech Corp. (OTC: TRTC), mCig, Inc. (OTC: MCIG), Radient Technologies Inc. (TSX-V: RTI.V), Aurora Cannabis Inc. (OTC: ACBFF) (TSX-V: ACB.V).
Radient Technologies Inc. (TSX-V: RTI.V) (OTC: RDDTF) closed up over 16% at $0.56 on Monday trading over 3.6 Million shares on the Canadian TSX Venture exchange by the market close. Radient Technologies announced yesterday the completion of the second phase of its previously announced joint venture research agreement with Aurora Cannabis Inc. (TSX-V: ACB. V)(OTCQX ACBFF). As previously announced, Radient and Aurora entered into a memorandum of understanding ('MOU') with regard to the exclusive joint development and commercialization of superior and standardized cannabinoid extracts for the Canadian market. In accordance with the MOU, the parties entered into a joint venture research agreement to confirm the effectiveness of Radient's MAP™ technology for cannabis extraction.
Vinergy Resources Ltd. (OTCQB: VNNYF) (CSE: VIN) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that, due to increased demand, the non-brokered private placement offering announced on May 11, 2017 has been increased to USD $400,000. The Company will now issue up to 800,000 units (the 'Units') at a price of USD $0.50 per Unit for gross proceeds of up to USD $400,000 (the 'Offering'). Each Unit will consist of one common share in the capital of the Company (a 'Share') and one transferable common share purchase warrant (a 'Warrant'), with each warrant exercisable into one additional share at a price of USD $1.00 for a period of three years from the date of closing (subject to acceleration in certain circumstances). Read this and more news for Vinergy Resources at:http://www.marketnewsupdates.com/news/vnnyf.html
Vinergy Resources recently announced that it has signed a definitive agreement with 1099955 B.C. LTD. dba MJ BioPharma ('MJ BioPharma') whereby Vinergy will purchase 100% of MJ BioPharma, a cannabis technology company. Pursuant to the terms of the Agreement, the Company will acquire all of the issued and outstanding securities of MJ BioPharma. MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers.
In conjunction with acquisition of MJ Biopharma, the Company announced it has developed a disruptive solvent-based extraction system. The project currently underway for an existing customer, utilizes an ethanol / CO2 co-solvent blend and specialized equipment to achieve medicinal products with significantly increased purity. The current iteration of the machine has the physical footprint of a standard shipping skid and incorporates safety and process control systems in one easy-to-use platform.
In other industry news and market performance of note in the sector:
Terra Tech Corp. (OTCQX: TRTC) closed up on Monday at $0.197 trading over 2.5 million shares by the market close. Terra Tech Corp last week announced its first quarter 2017 financial results for the period ended March 31, 2017. Derek Peterson, Chief Executive Officer of Terra Tech Corp., commented, "We are pleased to see the impact of our expansion strategy to open cannabis dispensaries in core target markets drive strong sales in the first quarter. We also reported higher sales of our wholesale IVXX-branded cannabis products as a result of its improved brand recognition coupled with expanded distribution channels. Total first quarter revenues were $6.8 million, representing a 340% increase over the prior year period and we are on track to meet our revenue guidance of $38 - $40 million for 2017."
mCig, Inc. (OTCQB: MCIG) closed up over 5% on Monday at $0.2425 trading over 3.4 million shares by the market close. mCig, Inc. yesterday announced some highlights of its year-end financial results: Net Sales increased to $4.5 million, a 158% increase year-to-year comparison, and a 1,294% increase for the 4th quarter compared to same period last fiscal year - Net income of $1.5 million compared to a $1.4 million loss from the previous year, and an increase of $2.9 million net earnings - Cash and cash equivalents of $1.6 million compared to $0.1 million from the previous year (a 1,369% increase), and a 400% increase from last quarter. mCig generated $2.1 million in cash from operating activities - mCig assets increased to $6.8 million, having 6 times more assets than it does liabilities. In addition to the highlights mentioned above, mCig Inc. was able to reduce its operating expenses by $730K (43%) from the previous year. In addition, mCig increased its gross profit by 20% to 36% compared to 16% from the previous year.
Collaboration update with Aurora:
http://mobile.tmxmoney.com/quote/readnews/?id=5996407996946730&symbol=RTI
Looks promising considering the PPS jump and volume levels today
New Chairman of the Board of Directors:
http://web.tmxmoney.com/article.php?newsid=7070844254440176&qm_symbol=RTI:APH
Sorry about my previous post I jumped the gun a little. After reading the news it became clear RTI is not yet supplying the oils to Aurora yet.
Oil currently being sold is not RTI's
They are still conducting trials, but should get some solid news soon.
CEO Terry Booth said some great things about RTI in their last PR
Aurora Commences Sales of Cannabis Oils
Source: PR Newswire (Canada)
TSXV: ACB
VANCOUVER, April 20, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSX-V: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that the Company has commenced sales of a new product line of ingestible cannabis oils called Aurora Drops.
The Company's newest offerings include three distinct product types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora's compassionate pricing program:
THC Drops (Sativa) – a high potency THC oil extracted from Cannabis Sativa flowers
THC Drops (Indica) – a high potency THC oil extracted from Cannabis Indica flowers
CBD Drops – a high potency oil extracted from Aurora's flagship CBD strain Temple (Cannatonic)
The Company's ingestible cannabis oils come in 30 ml glass bottles with a child resistant certified cap and dropper to allow for the easy and accurate dosing of small amounts of the high potency fluids, and are produced using CGMP compliant supercritical CO2 extraction technology, as well as using an MCT carrier oil sourced from coconut oil.
As with all of Aurora's cannabis products, the test results from the independent third-party lab for each batch of ingestible oil are publicly available. Test results can be accessed online at auroramj.com/strains, or through the Aurora Mobile app, a feature rich mobile experience for iOs and Android that displays inventory tracking and restocking events, and sends push notifications for new product releases.
"The launch of our first ingestible oil products represents a major milestone, which promises to add significantly to Aurora's top and bottom line results," said Neil Belot, Chief Global Business Development Officer. "We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency."
The Company recently signed a Memorandum of Understanding with Radient Technologies Inc. ("RTI") with regards to the joint development and commercialization in Canada of superior and standardized cannabinoid extracts produced using RTI's high-throughput, terpene-preserving, proprietary extraction technology.
"The strategic partnership with RTI has the potential to be a game changer in this high-margin, high-growth segment of the cannabis market, "said Terry Booth, CEO. "If the technology works as we anticipate, Aurora will be able to produce high volumes of terpene-rich cannabis derivatives at lower costs and much shorter harvest-to-market times than any company using current industry benchmark technologies. This would give us an even stronger competitive advantage in what may well become the dominant market segment. The launch of sales is the first step in establishing our brand in the derivatives market, and we are very pleased that we are able to expand our offering to a customer base looking for alternative methods to consume cannabis."
The companies' technical feasibility and commercial opportunities study currently underway is proceeding well, and is expected to be completed soon.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired and is undertaking completion of a third 40,000 square foot production facility in Pointe Claire, Quebec, near Montreal. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora's common shares trade on the TSX-V under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
These comments contain certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc.
Copyright 2017 Canada NewsWire
Oil now available on Auroras site thanks to RTI, RDDTF :)
Based on this info and the drop in PPS for RDDTF, RTI and the huge increase in volume I would say the testing trials are over and production is in full swing. We should be seeing gains in the comings weeks that bring us back close to or above our 52 week high.
https://auroramj.com/strains/
GLTA
RDDTF
RTI
ACBFF
ACB
Looks like the deal with Aurora for 6 million is going through now the share price will be at .45 soon. I am just going to hang on for a while.
Waiting for an update to the collaboration with ACBFF. if it is successful then great things will come. As of the last update things were looking good. Apparently their extraction process keeps the terpenes intact and that is a big plus during the oil extraction process.
Interesting business what the full story and take on this one guys?
#RDDTF: Thanks jp...:-} Looking like a good start here...
http://www.radientinc.com/public/download/documents/37406#referrer=http%3A%2F%2Fwww.radientinc.com%2Finvestors%2Fpresentation-fact-sheets
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
420
|
Created
|
03/17/17
|
Type
|
Free
|
Moderators |
Radient's patented, proprietary Microwave Assisted Processing or MAP™ technology is based on the selective and localized heating of the moisture present in all natural materials using microwaves as the energy source.
In general, microwaves interact with materials in three ways:
Microwaves do not heat by conduction or convection but rather dielectrically, which in simple terms means microwaves create heat when a material stops or slows the radiation causing it to deposit some of its energy, which is subsequently dissipated as heat. Because microwaves interact directly with the object being heated and because this interaction is related to both the chemical and dielectric properties of the object, it is possible to apply heat (or more precisely, energy) in ways that are not achievable by any other means. Furthermore, every material will absorb microwave energy to a different extent, with individual parts of that material will absorbing the energy differently.
Radient's technological advantage and expertise in selectively depositing microwave energy into different parts of a biomass' complicated chemical system form the core of our extraction advantage.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |